The drug received full approval this month, opening the doors to Medicare payments and expanding access for Alzheimer's patients who qualify for the twice-monthly infusion treatment.
that its treatment, donanemab, showed a 35% reduction in cognitive decline, or about seven-and-a-half months of slowing disease progression.
"We're expecting that Leqembi is also going to work in even earlier stage patients than where we are," Scott said. In fact, the lessons learned from Aduhelm's failure helped Eisai navigate the process. That includes knowing that Medicare would place restrictions on anything but a full, traditional approval.
It's why the company chose the price point it did and filed for full approval in order to get more potential patients on its drug.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
The Medicare Behemoth Finally Smiles on Primary CareNew care models aim to reduce the primary care-specialist pay gap.
Weiterlesen »
Weekend guide: Kick off 'Flirty Friday' at new restaurant's opening, or explore new Asian exhibitIt's the weekend! You could kick off 'Flirty Friday' at this restaurant's grand opening, journey through a free exhibit showcasing five different Asian countries, and so much more.
Weiterlesen »
New Jersey sues over New York City's congestion pricing plan | CNN BusinessNew Jersey is suing to stop New York City’s landmark congestion price plan to charge drivers entering downtown Manhattan.
Weiterlesen »
The New York Times’ New Hit Game Has a Problem Wordle Never DidI solve the puzzle often. I'm not so sure that's a good thing.
Weiterlesen »